NCT02529865已完成3 期
Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the Treatment of Male Stress Urinary Incontinence
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 8
- 主要终点
- Rate of patients with improvement in urine leakage volume as greater than 50% reduction from baseline by 24-hour pad test
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of periurethral injection of autologous Adipose Derived Regenerative Cells (ADRCs) in male stress urinary incontinence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males with stress urinary incontinence with insufficient effect by behavioral therapy or pharmacotherapy persisting more than 1 year after either of the following surgical procedure:
- •Patients with symptoms after radical prostatectomy for localized prostate cancer and currently without relapse/metastasis, and PSA level less than 0.1 ng/mL for over 1 year
- •Patients with symptoms after transurethral prostatectomy or laser prostatectomy for prostatic hyperplasia, and PSA level less than 4.0 ng/mL over 1 year
- •Age of 20 or above
- •Mild to moderate urinary incontinence on the 24-hour pad test
- •Patients who can keep a bladder diary in a satisfactory manner
- •Patients who are willing and able to give signed consent
排除标准
- •- Concurrent with any other types of urinary incontinence
- •History of urinary or reproductive surgery within 6 months
- •History of behavioral therapy or pharmacotherapy within 3 months
- •Concurrent with diabetes insipidus
- •History of radiotherapy in the lower urinary tract
- •History of ADRCs treatment for stress urinary incontinence
- •History of any type of cell therapy within 6 months
- •Participation in any other clinical trial within 3 months
- •Concurrent with lower urinary tract obstruction
- •Concurrent with urolithiasis, urinary tract infection or interstitial cystitis
- •History of recurrent urinary tract infection
- •History of malignant neoplasm within 5 years or a suspicion of it
- •Life expectancy of less than 1 year
- •Any other patients whom the trial investigator deemed ineligible to this study
结局指标
主要结局
Rate of patients with improvement in urine leakage volume as greater than 50% reduction from baseline by 24-hour pad test
时间窗: Baseline and 52 weeks (LOCF) after intervention
次要结局
- Rate of patients with improvement in the number of incontinence episodes per day as greater than 50% reduction from baseline(Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention)
- Urine leakage volume by 24-hour pad test(Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention)
- Rate of patients with improvement in urine leakage volume as greater than 50% reduction from baseline by 24-hour pad test(Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention)
- Number of pads used per day(Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention)
- QOL score (ICIQ-SF and KHQ)(Baseline, 26 and 52 weeks after intervention)
- Number of incontinence episodes per day(Baseline, 2, 4, 12, 26, 38 and 52 weeks after intervention)
- Patient overall satisfaction(Baseline, 26 and 52 weeks after intervention)
- Injection site evaluated by pelvis MRI scan(Baseline, 2, 26 and 52 weeks after intervention)
- Urodynamic parameters (MUCP, FPL and ALPP)(Baseline, 2, 4, 12, 26 and 52 weeks after intervention)
- Blood flow at the injection site measured by transrectal ultrasonography(Baseline,12, 26 and 52 weeks after intervention)
研究者
Momokazu Gotoh
MD, PhD, Professor at Department of Urology, Nagoya University Hospital
Nagoya University
研究点 (8)
Loading locations...
相似试验
Unknown
早期 1 期
A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem CellsParkinson DiseaseNCT03815071Allife Medical Science and Technology Co., Ltd.10
Unknown
早期 1 期
A Study of Autologous Induced Islet Body With Type 1 DiabetesType 1 DiabetesNCT03728296Allife Medical Science and Technology Co., Ltd.20
已完成
3 期
A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on DialysisAnemiaNCT00660023Hoffmann-La Roche124
进行中（未招募）
1 期
Prospective Study in Adults Evaluating Safety & Efficacy of NVD003 for Bone Reconstruction to Treat Lower Limb NonunionRecalcitrant Lower Limb NonunionNCT06335394Novadip Biosciences11
已完成
3 期
Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the KneeOsteoarthritisNCT05377489Grünenthal GmbH714